639 reports of this reaction
1.4% of all PIPERACILLIN SODIUM,TAZOBACTAM SODIUM reports
#20 most reported adverse reaction
MULTIPLE ORGAN DYSFUNCTION SYNDROME is the #20 most commonly reported adverse reaction for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 639 FDA adverse event reports linking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM to MULTIPLE ORGAN DYSFUNCTION SYNDROME. This represents approximately 1.4% of all 44,977 adverse event reports for this drug.
Patients taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM who experience multiple organ dysfunction syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE ORGAN DYSFUNCTION SYNDROME is a less commonly reported adverse event for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, but still significant enough to appear in the safety profile.
In addition to multiple organ dysfunction syndrome, the following adverse reactions have been reported for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM:
The following drugs have also been linked to multiple organ dysfunction syndrome in FDA adverse event reports:
MULTIPLE ORGAN DYSFUNCTION SYNDROME has been reported as an adverse event in 639 FDA reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE ORGAN DYSFUNCTION SYNDROME accounts for approximately 1.4% of all adverse event reports for PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, making it a notable side effect.
If you experience multiple organ dysfunction syndrome while taking PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.